Calgary, Alberta–(Newsfile Corp. – January 17, 2022) – Psygen Industries Ltd. (together with its subsidiaries, “ Psygen“) is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., received a dealer’s licence issued by Health Canada on January 17, 2022 (the “Dealer’s Licence“). Upon completion of its facility in Calgary, Psygen will begin onsite manufacturing of synthetic…


Previous articleOptimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
Next articleTwo thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression